Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
Tissue plasminogen activator was used to treat 228 children with 320 central venous catheter (CVC) occlusion events. Patency was restored in 91% of CVCs after 1 to 3 treatments, with no adverse events. Tissue plasminogen activator is effective in restoring patency to occluded CVCs and is a viable alternative to CVC removal or urokinase treatment.
Jacobs
B R
BR
Division of Critical Care Medicine, Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.
Haygood
M
M
Hingl
J
J
D000293:Adolescent; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D017063:Outcome Assessment, Health Care; D011994:Recombinant Proteins / Q000627:therapeutic use*; D019233:Retreatment; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D017211:Treatment Failure; D014654:Vascular Patency / Q000187:drug effects
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator